MEG Study of Acute STX209 Effects in ASD

NCT02278328 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Autism Disorder

Interventions

DRUG: STX209 (15mg)
DRUG: placebo
DRUG: STX209 (30mg)

Sponsor

Timothy Roberts

Collaborators

[object Object]
[object Object]